secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001213900-25-113606
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Nektar Therapeutics Chief Legal Officer Mark A. Wilson to Depart; Elizabeth Zhang to Succeed
--------------------------------------------------------------------------------

- Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025.
- Elizabeth Zhang, Vice President of Legal and Corporate Counsel, will take over Wilson's responsibilities.
- Zhang joined Nektar in 2021 and previously worked at Cravath, Swaine & Moore and Gibson, Dunn & Crutcher.
- Zhang holds a BA from Harvard College, an MS from the University of Oxford, and a JD from Harvard Law School.
- Wilson's departure is not the result of any disagreement with Nektar on operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025113606/0001213900-25-113606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025113606/ea0266707-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-113606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer